Wave Life Sciences (WVE) Capital Expenditures (2014 - 2026)
Wave Life Sciences' (WVE) quarterly Capital Expenditures came in at $884000.0 in Q2 2026, up 188.89% YoY from $306000.0 in Q2 2025, and up 101.83% on a QoQ basis from $438000.0 in Q1 2026.
Wave Life Sciences (WVE) Capital Expenditures (2014 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 13 years of Capital Expenditures data on file, last reported at $884000.0 in Q2 2026.
- Quarterly Capital Expenditures rose 188.89% year-over-year to $884000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.6 million (up 66.91% YoY) and the FY2025 annual result came in at $718000.0, down 23.45% from the prior year.
- Capital Expenditures climbed to $884000.0 in Q2 2026, from $438000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $884000.0 in Q2 2026 to a low of -$1000.0 in Q4 2025.
- A 5-year average of $303000.0 and a median of $277000.0 in 2025 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures surged 1260.0% — and 2025, when it sank 101.16%.
- Tracing WVE's Capital Expenditures over 5 years: stood at $204000.0 in 2022, then jumped by 74.51% to $356000.0 in 2023, then plunged by 75.84% to $86000.0 in 2024, then slumped by 101.16% to -$1000.0 in 2025, then jumped by 88500.0% to $884000.0 in 2026.
- The last three Capital Expenditures figures came in at $884000.0 (Q2 2026), $438000.0 (Q1 2026), and -$1000.0 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Wave Life Sciences | 1.05 Bn | 677.62 Mn | - | 884,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 884,000.00 |
| Jun 30, 2026 | 884,000.00 |
| Mar 31, 2026 | 438,000.00 |
| Mar 31, 2026 | 438,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Sep 30, 2025 | 248,000.00 |
| Sep 30, 2025 | 248,000.00 |
| Jun 30, 2025 | 306,000.00 |
| Jun 30, 2025 | 306,000.00 |
| Mar 31, 2025 | 165,000.00 |
| Mar 31, 2025 | 165,000.00 |
| Dec 31, 2024 | 86,000.00 |
| Dec 31, 2024 | 86,000.00 |
| Sep 30, 2024 | 383,000.00 |
| Sep 30, 2024 | 383,000.00 |
| Jun 30, 2024 | 52,000.00 |
| Jun 30, 2024 | 52,000.00 |
| Mar 31, 2024 | 417,000.00 |
| Mar 31, 2024 | 417,000.00 |